HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$9.70
-0.16 (-1.62%)
▼
5d:
-1.42%
30d:
+7.42%
90d:
-1.32%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Jul 30, 2026
14d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HLN shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: HLN shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.36
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$8.92
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $9.70, which is considered extended relative to its 30-day fair value range of $8.97 to $9.65. The stock's valuation (Forward PE: 15.9) is in line with its historical norms (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This pessimistic expectation contrasts with the company's recent 92.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $9.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HLN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.65 (+20.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $9.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HLN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.65 (+20.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.97 -
$9.65
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.1% below Wall St target ($11.65)
Trading Range Analysis
30-Day Trading Range
$8.97 -
$9.65
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.28
Resistance Level
$9.96
Current Trend
Strong Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.95
Wall Street Target
$11.65
(+20.1%)
Revenue Growth (YoY)
0.6%
Earnings Growth (YoY)
92.0%
Profit Margin
15.1%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
16.0 vs 16.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$9.55
(-2%)
2-Year Target
$9.41
(-3%)
3-Year Target
$9.27
(-4%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$9.71
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 10.4%)
$17.84
(+84%)
Base:
(SPY PE: 16.0, Growth: 10.4%)
$13.07
(+35%)
Bear:
(PE: 13.6, Growth: 10.4%)
$11.11
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 20.12 | Current EPS (TTM): $0.49
Bull Case
$13.46
(+39%)
Analyst growth 24.1%, PE expands to 22.1
Base Case
$12.24
(+26%)
Market implied 24.1%, PE stable at 20.1
Bear Case
$6.70
(-31%)
Severe decline -20.0%, PE contracts to 17.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.0 to 16.7
Stabilization Target:
$10.16
(+4.7%)
PE Expansion Potential:
+4.7%
Share & Embed Analysis
Last updated: July 14, 2026 7:21 PM ET
Data refreshes hourly during market hours. Next update: 8:21 PM
Data refreshes hourly during market hours. Next update: 8:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
